Barclays PLC Aerie Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 09, 2021	BUY	$11.32 - $16.63 $202,628 - $297,677	17,900 Added 8950.0%	18,100 $206,000
Q1 2019 May 15, 2019	SELL	$36.32 - $49.25 $21,792 - $29,550	-600 Reduced 75.0%	200 $10,000
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $9,900 - $18,012	300 Added 60.0%	800 $29,000
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $10.3 Million - $13.6 Million	-183,800 Reduced 99.73%	500 $31,000
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $9.37 Million - $12 Million	184,300	184,300 $11 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.